| 2932.95.00 | 00 | Tetrahydrocannabinols (all isomers) | kg | Free | | 15.4￠/kg + 52% |
| 2932.99.08 | 00 | 2-Ethoxy-2,3-dihydro-3,3-dimethyl-5- benzofuranylmethanesulfonate | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 40.5% |
| 2932.99.35 | 00 | 2-Hydroxy-3-dibenzofurancarboxylic acid | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 66.5% |
| 2932.99.39 | 00 | Benzointetrahydropyranyl ester; and Xanthen-9-one | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2933.11.00 | 00 | Compounds containing an unfused pyrazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.19.35 | 00 | Drugs | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4￠/kg + 47.5% |
| 2933.19.45 | 00 | Drugs | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2933.21.00 | 00 | Compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.29.20 | 00 | Drugs | kg | 6% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4￠/kg + 51% |
| 2933.29.45 | 00 | Drugs | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2933.31.00 | 00 | Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.33.00 | 00 | Alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN), fentanyl (INN), ketobemidone (INN), methylphenidate (INN), pentazocine (INN), pethidine (INN), pethidine (INN) intermediate A, phencyclidine (INN) (PCP), phenoperidine (INN), pipradrol (INN), piritramide (INN), propiram (INN) and trimeperidine (INN); salts thereof | kg | Free | | 15.4￠/kg + 149.5% |
| 2933.39.08 | 00 | 1-(3-Sulfopropyl)pyridinium hydroxide; N,N'-Bis(2,2,6,6-tetramethyl-4-piperidinyl)-1,6- hexanediamine; 3,5-Dimethyl-2-hydroxymethyl-4-methoxy- pyridine (pyrmethyl alcohol); Dipentamethylenethiuram tetrasulfide; 2H-Indol-2-one,1,3-dihydro-1-phenyl-3-(4- pyridinylmethylene); 4-Picolyl chloride hydrochloride; and Piperidinoethyl chloride hydrochloride | kg | Free | | 15.4￠/kg + 52% |
| 2933.39.20 | 00 | p-Chloro-2-benzylpyridine; 4-Chloro-1-methylpiperidine hydrochloride; 1,4-Dimethyl-6-hydroxy-3-cyanopyrid-2-one; Di-(2,2,6,6-tetramethyl-4-hydroxy- piperidine)sebacate; 2-Methyl-5-ethylpyridine; 4-Phenylpropylpyridine; α-Phenylpyridylacetic acid, methyl ester; Picolinic acid; 2-Pyridinecarboxaldehyde; and 2,5-Pyridinedicarboxylic acid | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2933.39.31 | 00 | Drugs: | | | | |
| 2933.41.00 | 00 | Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2933.49.10 | 00 | Ethoxyquin (1,2-Dihydro-6-ethoxy-2,2,4- trimethylquinoline) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 55% |
| 2933.49.17 | 00 | Ethyl ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylate | kg | Free | | 15.4￠/kg + 52% |
| 2933.49.20 | 00 | Drugs: | | | | |
| 2933.49.20 | 00 | 5-Chloro-7-iodo-8-quinolinol (Iodochlorhydroxyquin); Decoquinate; Diiodohydroxyquin; and Oxyquinoline sulfate | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 46% |
| 2933.52 | | Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: | | | | |
| 2933.59.21 | 00 | Drugs: | | | | |
| 2933.61.00 | 00 | Compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.79.04 | 00 | 2,5-Dihydro-3,6-diphenylpyrrolo-(3,4-c)- pyrrole-1,4-dione | kg | Free | | 15.4￠/kg + 52% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4￠/kg + 52% |
